SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients.

摘要: The coronavirus disease-2019 (COVID-19) is a highly transmissible viral illness caused by SARS-CoV-2, which has been defined the World Health Organization as pandemic, considering its remarkable transmission speed worldwide. SARS-CoV-2 interacts with angiotensin-converting enzyme 2 and TMPRSS2, serine protease both expressed in lungs, gastro-intestinal tract, cardiac myocytes. Patients COVID-19 experienced adverse events (hypertension, venous thromboembolism, arrhythmia, myocardial injury, fulminant myocarditis), patients previous cardiovascular disease have higher risk of death. Cancer are extremely vulnerable high infection more negative prognosis than healthy people, magnitude effects depends on type cancer, recent chemotherapy, radiotherapy, or surgery other concomitant comorbidities (diabetes, diseases, metabolic syndrome). active cancer those treated cardiotoxic therapies may heart damages exacerbated non-cancer patients. We highlight side focusing main outcomes updated perspective retrospective studies. focus cardio-metabolic factors provide recommendations aimed to reduce events, morbidity, mortality.